Olema Pharmaceuticals, Inc. (OLMA) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 San Francisco, CA, 美国. 现任CEO为 Sean Bohen.
OLMA 拥有 IPO日期为 2020-11-19, 96 名全职员工, 在 NASDAQ Global Select, 市值为 $1.42B.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
